Eric Langer

The inaugural BioPharma By the Numbers provides a data-driven look at how automation in bioprocessing is driving efficiency, reducing errors, and addressing capacity challenges.

But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.

Single-use systems can be a cost savings for CMOs, and these savings can be passed on to clients and, ultimately, to patients.

Outsourcing of manufacturing activities is expected to increase in 2019.

The growth in adoption of single-use systems for commercial manufacturing will be dramatic in coming years.

This article highlights 15 years of changes in biopharmaceutical manufacturing.

Although widespread adoption of continuous bioprocessing has been slow, some processes have been an exception.

This key bioprocessing segment is expecting continued growth.

CMOs are working hard to improve performance by investigating new technologies for filtration and purification.

Biopharmaceutical manufacturers continue to put quality at the forefront of their relationships.

Growth may be slowing, but outsourcing activity remains healthy.

Better process development is creating industry benchmarks for bioprocessing.

Suppliers indicate prices for single-use equipment are likely to increase.

Biopharma companies are outsourcing more jobs to cut costs.

Automation and disposables continue to reduce human error.

Biopharma companies on both sides of the Atlantic ship more of their assay testing to outside service providers.

While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.

Is there enough talent to go around?

There are significant differences between small molecules and biologics fill/finish capacity.

Outsourcing is taking on a greater role in the biopharmaceutical manufacturing industry.

Biopharma continues to adopt single-use technologies, but also seeks more innovation and improvements in products.

Annual study shows geographic proximity not a factor in CMO selection.

The author highlights the top 10 outsourcing trends found during a survey of biopharmaceutical manufacturers.

With budgets growing, clients see CMOs' costs as less crucial.

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Research uncovers trends and factors affecting the pre-packed disposable chromatography columns market for downstream bioprocessing.

Research uncovers trends and factors affecting the pre-packed disposable chromatography columns market for downstream bioprocessing.

CMOs may find opportunities in alternative expression services.

Data from BioPlan Associates' 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production suggest that the interest in disposable devices has begun to extend to biopharma operations beyond basic single-use bags and connectors.

While the severity of capacity problems related to downstream processing appears to have eased, it continues to be a problem and chromatography columns are the most frequent culprits.